COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
- Details
- Publication Year 2023-08-04,Volume 228,Issue #Suppl 1,Page S55-S69
- Journal Title
- Journal of Infectious Diseases
- Publication Type
- Review
- Abstract
- Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy.
- Publisher
- Oxford University Press
- Keywords
- Humans; COVID-19 Vaccines; *Receptors, Chimeric Antigen; *covid-19; SARS-CoV-2; *Neoplasms/complications/therapy; *Hematologic Neoplasms/complications/therapy; Vaccination; Immunity; *Hematopoietic Stem Cell Transplantation; chimeric-antigen receptor T-cell therapy; hematologic malignancies; hematopoietic stem cell transplant; mRNA COVID-19 vaccines; solid tumors
- Department(s)
- Infectious Diseases
- PubMed ID
- 37539765
- Publisher's Version
- https://doi.org/10.1093/infdis/jiad174
- Open Access at Publisher's Site
- https://doi.org/10.1093/infdis/jiad174
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-10-19 07:23:14
Last Modified: 2023-10-19 07:23:32